Cancer immunotherapy predictive parameters

Details Cancer immunotherapy predictive parameters Cancer immunotherapy predictive parameters

2007-10-03

2011-11-22

Canella, Karen (Department: 1643)

Drug, bio-affecting and body treating compositions

In vivo diagnosis or in vivo testing

Testing efficacy or toxicity of a compound or composition

C435S007210, C435S007240

Reexamination Certificate

active

08062625

ABSTRACT:
The invention relates to a method for predicting the efficacy of a cancer immunotherapy of an individual with respect to clinical benefit, which comprises the following steps: —providing a blood sample of said individual, —(a1) determining the number of lymphocytes in the blood of said individual, and/or (a2) determining the number of neutrophils in the blood of said individual, and —(b1) identifying the individual as having a predictive clinical benefit from the immunotherapy, if the number Of lymphocytes is below or equal to a lymphocyte baseline level of 1.4 to 1.8×109per liter blood, especially below or equal to 1.6×109per liter blood; or (b2) identifying the individual as having a predictive clinical benefit from the immunotherapy, if the number of neutrophils is below or equal to a neutrophil baseline level of from 4.0 to 6.0×109per liter blood, especially below or equal to 5.0×109neutrophils per liter blood; or (b3) identifying the individual as not having a predictive clinical benefit, if the number of lymphocytes is above a lymphocyte baseline level of 1.4 to 1.8×109per liter blood, especially above 1.6×109per liter blood and the number of neutrophils is above a neutrophil baseline level of from 4.0 to 6.0×109per liter blood, especially above 5.0×109neutrophils per liter blood.

REFERENCES:
patent: WO 02/38189 (2002-05-01), None
Abstract of Wheeler (Salud p'ublica de M'exico, (Jul.-Aug. 1997) 39 (4) 283-7).
Efferson et al (Anticancer research, 2005, vol. 25, pp. 715-24).
Bachman et al (Journal of Immunology, 2005, vol. 175, pp. 4677-4685).
Morse et al (International Journal of Gastrointestinal Cancer, 2002, vol. 32, pp. 1-6).
U.S. Appl. No. 12/444,316, filed Apr. 3, 2009, Loibner.
J. Atzpodien, et al., “Metastatic renal carcinoma comprehensive prognostic system”, British Journal of Cancer, XP-002460745, 2003, pp. 348-353.
Piero Dalerba, et al., “Immunology and immunotherapy of colorectal cancer”, Critical Reviews in Oncology/Hematology, vol. 46, XP-002461095, 2003, pp. 33-57.
F. Donskov, et al. “Monocytes and neutrophils as ‘bad guys’ for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma—results from a randomized phase II trial”, British Journal of Cancer, vol. 94, XP-002460747, 2006, pp. 218-226, January.
Luca A. Fumagalli, et al., “Lymphocyte Counts Independently Predict Overall Survival in Advanced Cancer Patients: A Biomarker for IL-2 Immunotherapy”, Journal of Immunotherapy, vol. 26, No. 5, XP009092899, 2003, pp. 394-402.
Himmler, et al., “A randomized placebo-controlled phase II study with the cancer vaccine candidate IGN101 in patients with epithelial cancers”, Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, vol. 23, No. 16S, Part I of II (Jun. 1 Supplement), 2005, 2 pages, submitting Abstract only.
Andres Riesco, “Five-Year Cancer Cure: Relation to Total Amount of Peripheral Lymphocytes and Neutrophils”, Cancer, vol. 25, No. 1, Jan. 1970, pp. 135-140.
Schmidt, et al., “Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model”, British Journal of Cancer, vol. 93, XP-002460746, Jul. 19, 2005, pp. 273-278.
S. R. Walsh, et al., “Neutrophil-Lymphocyte Ratio as a Prognostic Factor in Colorectal Cancer” Journal of Surgical Oncology, vol. 91, No. 3, XP-002460743, 2005, pp. 181-184, Sep. 1.

Affiliated with

Also associated with

Rating

Cancer immunotherapy predictive parameters does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancer immunotherapy predictive parameters, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer immunotherapy predictive parameters will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4276363